Reliance Life Sciences, a Reliance Group of companies, today said it has acquired UK-based GeneMedix Plc for 14.6 million pounds (about Rs 126.83 crore).This acquisition is by way of subscription by Reliance Life Sciences to 1,168 million additional equity shares of GeneMedix at 1.25 pence per share, the company said.This represents a share holding of 74% of the enlarged equity of GeneMedix for Reliance Life Sciences.The acquisition deal also involves a five year warrant option for Reliance Life Sciences for a further 1,404 million shares at 1.25 pence per share to enable infusion of an additional 17.5 million pounds, which would take the shareholding of Reliance Life Science in GeneMedix to 86%."We are pleased to be able to work closely with GeneMedix in realising its aspirations of being a major bio-generics player," K V Subramaniam, president & CEO, Reliance Life Science, said.Following the acquisition, GeneMedix would transfer its listing to the Alternate Investment Market (AIM) on the London Stock Exchange, to give it greater flexibility in aligning its capital structure and funding plans to support a diverse and deep bio-pharmaceutical development programme.Reliance Life Sciences is a research driven organisation, which participates in medical, plant and industrial biotechnology opportunities.